Primary periodic paralyses

Acta Neurologica Scandinavica

Volumn 117, Issue 3, 2008, Pages 145-158

  Finsterer, J ^a,b  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^b NONE   (Austria)

Author keywords

Channelopathies; Electrolytes; Genetics; Myotonia; Neuromuscular disorders; Periodic weakness

Indexed keywords

3,4 DIAMINOPYRIDINE; ACETAZOLAMIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL; CARBOHYDRATE; CARBONATE DEHYDRATASE INHIBITOR; CHOLINESTERASE INHIBITOR; DICLOFENAMIDE; DIURETIC AGENT; EPHEDRINE; FLUOXETINE; GLUCOCORTICOID; GLUCONATE CALCIUM; INSULIN; POTASSIUM; POTASSIUM CHANNEL; PROTEIN; SALBUTAMOL; SLC4A1 PROTEIN; SODIUM CHANNEL; TERBUTALINE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

ANDERSEN SYNDROME; CHROMOSOME 17Q; CHROMOSOME XP; CONGENITAL MYASTHENIC SYNDROME; CORRELATION ANALYSIS; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; ELECTROMYOGRAM; EMOTIONAL STRESS; EXERCISE; FLACCID PARALYSIS; FOOD; GENE MUTATION; GENETIC COUNSELING; GLYCOGEN STORAGE DISEASE TYPE 4; HUMAN; HYPERKALEMIA; HYPOKALEMIA; KIDNEY TUBULE ACIDOSIS; MOLECULAR GENETICS; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYOTONIA; PATHOGENESIS; PERIODIC PARALYSIS; POTASSIUM BLOOD LEVEL; PREGNANCY; QT INTERVAL; REVIEW; SKELETAL MUSCLE; THOMSEN DISEASE; THYROTOXICOSIS; X CHROMOSOME LINKED DISORDER;

CALCIUM CHANNELS; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, X; GENETIC COUNSELING; GLYCOGEN STORAGE DISEASE TYPE IV; HUMANS; HYPOKALEMIC PERIODIC PARALYSIS; MYOTONIC DISORDERS; PARALYSES, FAMILIAL PERIODIC; POINT MUTATION;

EID: 38849162121     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2007.00963.x     Document Type: Review

References (99)

1. Jurkat-Rott K, Lehmann-Horn F. Hyperkalemic periodic paralysis. Gene reviews, 2005. Available at: http://www.genetests.org.
2. Tawil R, Venenace SL. Andersen-Tawil syndrome. Gene reviews, 2007. Available at: http://www.genetests.org.
3. Musgrave W. A periodic palsy. The Philosophical Transactions and Collections to the End of the Year. 1700 2 : 33.
4. Romberg MH. Lehrbuch der Nervenkrankheiten des Menschen, 3rd edn, 1840-1846. Berlin : Duncker, 1857.
5. Sternberg D, Tabti N, Hainque B, Fontaine B. Hypokalemic periodic paralysis. Gene reviews. Available at: http://www.ncbi.nlm.nih.gov/books/bv. fcgi?rid=gene.chapter.hpp, 2006.
6. Westphal CSO. Über einen merkwürdigen Fall von periodischer Lähmung aller vier Extremitäten mit gleichzeitigem Erlöschen der elektrischen Erregbarkeit während der Lähmung. Berliner Klin Wochenschr 1885 22 : 489 91, 509 511.
7. Jurkat-Rott K, Lehmann-Horn F, Elbaz A et al. A calcium channel mutation causing hypokalemic periodic paralysis. Hum Mol Genet 1994 3 : 1415 9.
8. Ptacek LJ, Tawil R, Griggs RC et al. Sodium channel mutations in acetazolamide-responsive myotonia congenita, paramyotonia congenita, and hyperkalemic periodic paralysis. Neurology 1994 44 : 1500 3.
9. Ptacek LJ, George AL Jr., Griggs RC et al. Identification of a mutation in the gene causing hyperkalemic periodic paralysis. Cell 1991 67 : 1021 7.
10. Ptacek LJ, George AL Jr., Barchi RL et al. Mutations in an S4 segment of the adult skeletal muscle sodium channel cause paramyotonia congenita. Neuron 1992 8 : 891 7.
11. Tyler FH, Stephens FE, Gunn FD, Perkoff GT. Studies in disorders of muscle. VII. Clinical manifestations and inheritance of a type of periodic paralysis without hypopotassemia. J Clin Invest 1951 30 : 492 502.
12. Gamstorp I. Adynamia episodica hereditaria. Acta Paediatr Scand 1956 108 (Suppl. 45 1 126.
13. Lehmann-Horn F, Rudel R, Ricker K. Non-dystrophic myotonias and periodic paralyses. A European Neuromuscular Center Workshop held 4-6 October 1992, Ulm, Germany. Neuromuscul Disord 1993 3 : 161 8.
14. Fontaine B, Khurana TS, Hoffman EP et al. Hyperkalemic periodic paralysis and the adult muscle sodium channel α-subunit gene. Science 1990 250 : 1000 2.
15. Andersen ED, Krasilnikoff PA, Overvad H. Intermittent muscular weakness, extrasystoles, and multiple developmental anomalies. A new syndrome? Acta Paediatr Scand 1971 60 : 559 64.
16. Plaster NM, Tawil R, Tristani-Firouzi M et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 2001 105 : 511 9.
17. Celesia GG. Disorders of membrane channels or channelopathies. Clin Neurophysiol 2001 112 : 2 18.
18. Jurkat-Rott K, Lehmann-Horn F. Genotype-phenotype correlation and therapeutic rationale in hyperkalemic periodic paralysis. Neurotherapeutics 2007 4 : 216 24.
19. 2+ channel expressed in Xenopus laevis oocytes. J Physiol 1999 520 : 321 36.
20. Bendahhou S, Fournier E, Gallet S, Menard D, Larroque MM, Barhanin J. Corticosteroid-exacerbated symptoms in an Andersen's syndrome kindred. Hum Mol Genet 2007 16 : 900 6.
21. Tristani-Firouzi M, Jensen JL, Donaldson MR et al. Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest 2002 110 : 381 8.
22. Heatwole CR, Moxley RT 3rd. The nondystrophic myotonias. Neurotherapeutics 2007 4 : 238 51.
23. Cannon SC, Brown RH Jr., Corey DP. A sodium channel defect in hyperkalemic periodic paralysis: potassium-induced failure of inactivation. Neuron 1991 6 : 619 26.
24. Bradley WG, Taylor R, Rice DR et al. Progressive myopathy in hyperkalemic periodic paralysis. Arch Neurol 1990 47 : 1013 7.
25. McClatchey AI, McKenna-Yasek D, Cros D et al. Novel mutations in families with unusual and variable disorders of the skeletal muscle sodium channel. Nat Genet 1992 2 : 148 52.
26. Wagner S, Lerche H, Mitrovic N, Heine R, George AL, Lehmann-Horn F. A novel sodium channel mutation causing a hyperkalemic paralytic and paramyotonic syndrome with variable clinical expressivity. Neurology 1997 49 : 1018 25.
27. Lehmann-Horn F, Rudel R, Jurkat-Rott K. Non-dystrophic myotonias and periodic paralyses. In : Engel AG, Franzini-Armstrong C, eds. Myology: basic and clinical, 3rd edn. New York : McGraw-Hill, 2004 1257 300, Chap 46.
28. Ricker K, Camacho LM, Grafe P, Lehmann-Horn F, Rudel R. Adynamia episodica hereditaria: what causes the weakness? Muscle Nerve 1989 12 : 883 91.
29. McManis PG, Lambert EH, Daube JR. The exercise test in periodic paralysis. Muscle Nerve 1986 9 : 704 10.
30. Ryan MM, Taylor P, Donald JA et al. A novel syndrome of episodic muscle weakness maps to xp22.3. Am J Hum Genet 1999 65 : 1104 13.
31. Lehmann-Horn F, Kuther G, Ricker K, Grafe P, Ballanyi K, Rudel R. Adynamia episodica hereditaria with myotonia: a non-inactivating sodium current and the effect of extracellular pH. Muscle Nerve 1987 10 : 363 74.
32. Ashwood EM, Russell WJ, Burrow DD. Hyperkalaemic periodic paralysis and anaesthesia. Anaesthesia 1992 47 : 579 84.
33. Riggs JE, Griggs RC, Moxley RT. Acetazolamide-induced weakness in paramyotonia congenita. Ann Intern Med 1977 86 : 169 73.
34. Klingler W, Lehmann-Horn F, Jurkat-Rott K. Complications of anaesthesia in neuromuscular disorders. Neuromuscul Disord 2005 15 : 195 206.
35. Eulenburg A. Ueber eine familiare, durch 6 generationen verfolgbare Form congenitaler Paramyotonie. Neurologisches Centralblatt 1886 12 : 265 72.
36. Borg K, Hovmoller M, Larsson L, Edstrom L. Paramyotonia congenita (Eulenburg): clinical, neurophysiological and muscle biopsy observations in a Swedish family. Acta Neurol Scand 1993 87 : 37 42.
37. Davies NP, Eunson LH, Gregory RP, Mills KR, Morrison PJ, Hanna MG. Clinical, electrophysiological, and molecular genetic studies in a new family with paramyotonia congenita. J Neurol Neurosurg Psychiatry 2000 68 : 504 7.
38. Samaha FJ. Von Eulenberg's paramyotonia. A clinical study of restricted myotonia and episodic paralysis successfully controlled by chlorothiazide. Trans Am Neurol Assoc 1964 89 : 87 91.
39. Lehmann-Horn F, Jurkat-Rott K. Voltage-gated ion channels and hereditary disease. Physiol Rev 1999 79 : 1317 72.
40. Finsterer J. Hereditäre Ionenkanal-Erkrankungen des peripheren Nervensystems. J Neurol Neurochir Psychiatr 2003 4 : 7 14.
41. Ma D, Tang XD, Rogers TB, Welling PA. An andersen-Tawil syndrome mutation in Kir2.1 (V302M) alters the G-loop cytoplasmic K+ conduction pathway. J Biol Chem 2007 282 : 5781 9.
42. Links TP, Zwarts MJ, Wilmink JT, Molenaar WM, Oosterhuis HJ. Permanent muscle weakness in familial hypokalaemic periodic paralysis. Clinical, radiological and pathological aspects. Brain 1990 113 : 1873 89.
43. Buruma OJ, Bots GT. Myopathy in familial hypokalaemic periodic paralysis independent of paralytic attacks. Acta Neurol Scand 1978 57 : 171 9.
44. Jurkat-Rott K, Mitrovic N, Hang C et al. Voltage-sensor sodium channel mutations cause hypokalemic periodic paralysis type 2 by enhanced inactivation and reduced current. Proc Natl Acad Sci USA 2000 97 : 9549 54.
45. Streeten DH, Speller PJ, Fellerman H. Use of corticotropin-induced potassium changes in the diagnosis of both hypo- and hyperkalemic periodic paralysis. Eur Neurol 1993 33 : 103 8.
46. Ikeda K, Iwasaki Y, Kinoshita M et al. Acetazolamide-induced muscle weakness in hypokalemic periodic paralysis. Intern Med 2002 41 : 743 5.
47. Sugiura Y, Aoki T, Sugiyama Y, Hida C, Ogata M, Yamamoto T. Temperature-sensitive sodium channelopathy with heat-induced myotonia and cold-induced paralysis. Neurology 2000 54 : 2179 81.
48. Cruz-Martinez A, Arpa J. Muscle fiber conduction velocity in situ in hypokalemic periodic paralyses. Acta Neurol Scand 1997 96 : 229 35.
49. Faugere MC, Pellissier JF, Toga M. Subsequent morphological changes in periodic paralysis. A study of seven cases. Acta Neuropathol 1981 7 (Suppl. Berl 301 4.
50. Sternberg D, Maisonobe T, Jurkat-Rott K et al. Hypokalaemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A. Brain 2001 124 : 1091 9.
51. Streib EW. AAEE minimonograph #27: differential diagnosis of myotonic syndromes. Muscle Nerve 1987 10 : 603 15.
52. Fournier E, Arzel M, Sternberg D et al. Electromyography guides toward subgroups of mutations in muscle channelopathies. Ann Neurol 2004 56 : 650 61.
53. Miller TM, Dias da Silva MR, Miller HA et al. Correlating phenotype and genotype in the periodic paralyses. Neurology 2004 63 : 1647 55.
54. Wang Q, Liu M, Xu C et al. Novel CACNA1S mutation causes autosomal dominant hypokalemic periodic paralysis in a Chinese family. J Mol Med 2005 83 : 203 8.
55. Bulman DE, Scoggan KA, van Oene MD et al. A novel sodium channel mutation in a family with hypokalemic periodic paralysis. Neurology 1999 53 : 1932 6.
56. Bendahhou S, Cummins TR, Griggs RC, Fu YH, Ptacek LJ. Sodium channel inactivation defects are associated with acetazolamide-exacerbated hypokalemic periodic paralysis. Ann Neurol 2001 50 : 417 20.
57. Davies NP, Eunson LH, Samuel M, Hanna MG. Sodium channel gene mutations in hypokalemic periodic paralysis: an uncommon cause in the UK. Neurology 2001 57 : 1323 5.
58. Kim MK, Lee SH, Park MS et al. Mutation screening in Korean hypokalemic periodic paralysis patients: a novel SCN4A Arg672Cys mutation. Neuromuscul Disord 2004 14 : 727 31.
59. Kawamura S, Ikeda Y, Tomita K, Watanabe N, Seki K. A family of hypokalemic periodic paralysis with CACNA1S gene mutation showing incomplete penetrance in women. Intern Med 2004 43 : 218 22.
60. Monnier N, Procaccio V, Stieglitz P, Lunardi J. Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet 1997 60 : 1316 25.
61. + channels in patients with hypokalemic periodic paralysis. J Clin Invest 1999 103 : 675 82.
62. Kuzmenkin A, Muncan V, Jurkat-Rott K et al. Enhanced inactivation and pH sensitivity of Na(+) channel mutations causing hypokalaemic periodic paralysis type II. Brain 2002 125 : 835 43.
63. Venance SL, Jurkat-Rott K, Lehmann-Horn F, Tawil R. SCN4A-associated hypokalemic periodic paralysis merits a trial of acetazolamide. Neurology 2004 63 : 1977.
64. Tawil R, McDermott MP, Brown R Jr. et al. Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis. Ann Neurol 2000 47 : 46 53.
65. Lambert C, Blanloeil Y, Horber RK, Berard L, Reyford H, Pinaud M. Malignant hyperthermia in a patient with hypokalemic periodic paralysis. Anesth Analg 1994 79 : 1012 4.
66. Rajabally YA, El Lahawi M. Hypokalemic periodic paralysis associated with malignant hyperthermia. Muscle Nerve 2002 25 : 453 5.
67. Marchant CL, Ellis FR, Halsall PJ, Hopkins PM, Robinson RL. Mutation analysis of two patients with hypokalemic periodic paralysis and suspected malignant hyperthermia. Muscle Nerve 2004 30 : 114 7.
68. Hofer C, Zalunardo MP, Zollinger A. Total intravenous anaesthesia in a patient with familial hypokalaemic periodic paralysis. Anaesthesia 2001 56 : 1082 5.
69. Andelfinger G, Tapper AR, Welch RC, Vanoye CG, George AL Jr., Benson DW. KCNJ2 mutation results in Andersen syndrome with sex-specific cardiac and skeletal muscle phenotypes. Am J Hum Genet 2002 71 : 663 8.
70. Davies NP, Imbrici P, Fialho D et al. Andersen-Tawil syndrome: new potassium channel mutations and possible phenotypic variation. Neurology 2005 65 : 1083 9.
71. Lehmann-Horn F, Jurkat-Rott K, Rudel R. Periodic paralysis: understanding channelopathies. Curr Neurol Neurosci Rep 2002 2 : 61 9.
72. Ptacek LJ, Fu YH. Channelopathies: episodic disorders of the nervous system. Epilepsia 2001 42 (Suppl. 5 35 43.
73. Bendahhou S, Fournier E, Sternberg D et al. In vivo and in vitro functional characterization of Andersen's syndrome mutations. J Physiol 2005 565 : 731 41.
74. Ai T, Fujiwara Y, Tsuji K et al. Novel KCNJ2 mutation in familial periodic paralysis with ventricular dysrhythmia. Circulation 2002 105 : 2592 4.
75. Donaldson MR, Jensen JL, Tristani-Firouzi M et al. PIP2 binding residues of Kir2.1 are common targets of mutations causing Andersen syndrome. Neurology 2003 60 : 1811 6.
76. Hosaka Y, Hanawa H, Washizuka T et al. Function, subcellular localization and assembly of a novel mutation of KCNJ2 in Andersen's syndrome. J Mol Cell Cardiol 2003 35 : 409 15.
77. Pegan S, Arrabit C, Slesinger PA, Choe S. Andersen's syndrome mutation effects on the structure and assembly of the cytoplasmic domains of Kir2.1. Biochemistry 2006 45 : 8599 606.
78. Lange PS, Er F, Gassanov N, Hoppe UC. Andersen mutations of KCNJ2 suppress the native inward rectifier current IK1 in a dominant-negative fashion. Cardiovasc Res 2003 59 : 321 7.
79. Donaldson MR, Yoon G, Fu YH, Ptacek LJ. Andersen-Tawil syndrome: a model of clinical variability, pleiotropy, and genetic heterogeneity. Ann Med 2004 36 (Suppl. 1 92 7.
80. Ballester LY, Benson DW, Wong G et al. Trafficking-competent and trafficking-defective KCNJ2 mutations in Andersen syndrome. Hum Mutat 2006 27 : 388.
81. Preisig-Muller R, Schlichthorl G, Goerge T et al. Heteromerization of Kir2.x potassium channels contributes to the phenotype of Andersen's syndrome. Proc Natl Acad Sci USA 2002 28 : 99.
82. Xia M, Jin Q, Bendahhou S et al. A Kir2.1 gain-of-function mutation underlies familial atrial fibrillation. Biochem Biophys Res Commun 2005 332 : 1012 9.
83. Chun TU, Epstein MR, Dick M 2nd. et al. Polymorphic ventricular tachycardia and KCNJ2 mutations. Heart Rhythm 2004 1 : 235 41.
84. Woosley RL. Drugs that prolong the QT interval and/or induce torsades de pointes. Online database. Available at: http://www.qtdrugs.org, 2001.
85. Diedrich DA, Wedel DJ. Thyrotoxic periodic paralysis and anesthesia report of a case and literature review. J Clin Anesth 2006 18 : 286 92.
86. Lichtstein DM, Arteaga RB. Rhabdomyolysis associated with hyperthyroidism. Am J Med Sci 2006 332 : 103 5.
87. Lam L, Nair RJ, Tingle L. Thyrotoxic periodic paralysis. Proc (Bayl Univ Med Cent) 2006 19 : 126 9.
88. Hsu YJ, Lin YF, Chau T, Liou JT, Kuo SW, Lin SH. Electrocardiographic manifestations in patients with thyrotoxic periodic paralysis. Am J Med Sci 2003 326 : 128 32.
89. Sthaneshwar P, Prathibha R, Yap SF. Thyrotoxic periodic paralysis: a report of three Malaysian cases and a review of OTS pathology. Malays J Pathol 2005 27 : 29 32.
90. Liu Z, Braverman LE, Malabanan A. Thyrotoxic periodic paralysis in a Hispanic man after the administration of prednisone. Endocr Pract 2006 12 : 427 31.
91. Yu TS, Tseng CF, Chuang YY, Yeung LK, Lu KC. Potassium chloride supplementation alone may not improve hypokalemia in thyrotoxic hypokalemic periodic paralysis. J Emerg Med 2007 32 : 263 5.
92. Lane AH, Markarian K, Braziunene I. Thyrotoxic periodic paralysis associated with a mutation in the sodium channel gene SCN4A. J Pediatr Endocrinol Metab 2004 17 : 1679 82.
93. Vicart S, Sternberg D, Fournier E et al. New mutations of SCN4A cause a potassium-sensitive normokalemic periodic paralysis. Neurology 2004 63 : 2120 7.
94. Shishiba Y. Recent progress on the searchs of pathogenesis of thyrotoxic periodic paralysis. Nippon Rinsho 2006 64 : 2339 47.
95. Lu KC, Hsu YJ, Chiu JS, Hsu YD, Lin SH. Effects of potassium supplementation on the recovery of thyrotoxic periodic paralysis. Am J Emerg Med 2004 22 : 544 7.
96. Nakagawa Y, Carvalho M, Malasit P et al. Kidney stone inhibitors in patients with renal stones and endemic renal tubular acidosis in northeast Thailand. Urol Res 2004 32 : 112 6.
97. Nilwarangkur S, Nimmannit S, Chaovakul V et al. Endemic primary distal renal tubular acidosis in Thailand. Q J Med 1990 74 : 289 301.
98. Abicht A, Lochmüller H. Congenital myasthenic syndromes. Gene reviews. Available at: http://www.genetests.org. 2006
99. Tsujino A, Maertens C, Ohno K et al. Myasthenic syndrome caused by mutation of the SCN4A sodium channel. Proc Natl Acad Sci USA 2003 100 : 7377 82.